Compile Data Set for Download or QSAR
Report error Found 44 Enz. Inhib. hit(s) with all data for entry = 50019878
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624069(CHEMBL5425846)
Affinity DataEC50:  5nMAssay Description:Agonist activity at GST-tagged human FXR-LBD in presence of luorescein-SRC2-2 coactivator peptide by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624071(CHEMBL5409962)
Affinity DataEC50:  6nMAssay Description:Agonist activity at GST-tagged human FXR-LBD in presence of luorescein-SRC2-2 coactivator peptide by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624068(CHEMBL5422021)
Affinity DataEC50:  8nMAssay Description:Agonist activity at GST-tagged human FXR-LBD in presence of luorescein-SRC2-2 coactivator peptide by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624058(CHEMBL5412701)
Affinity DataEC50:  15nMAssay Description:Agonist activity at GST-tagged human FXR-LBD in presence of luorescein-SRC2-2 coactivator peptide by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624070(CHEMBL5406974)
Affinity DataEC50:  16nMAssay Description:Agonist activity at GST-tagged human FXR-LBD in presence of luorescein-SRC2-2 coactivator peptide by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624069(CHEMBL5425846)
Affinity DataEC50:  18nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624064(CHEMBL5433843)
Affinity DataEC50:  20nMAssay Description:Agonist activity at GST-tagged human FXR-LBD in presence of luorescein-SRC2-2 coactivator peptide by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624065(CHEMBL5433507)
Affinity DataEC50:  21nMAssay Description:Agonist activity at GST-tagged human FXR-LBD in presence of luorescein-SRC2-2 coactivator peptide by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624062(CHEMBL5432874)
Affinity DataEC50:  28nMAssay Description:Agonist activity at GST-tagged human FXR-LBD in presence of luorescein-SRC2-2 coactivator peptide by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624076(CHEMBL5437931)
Affinity DataEC50:  29nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624063(CHEMBL5412609)
Affinity DataEC50:  30nMAssay Description:Agonist activity at GST-tagged human FXR-LBD in presence of luorescein-SRC2-2 coactivator peptide by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624057(CHEMBL5433391)
Affinity DataEC50:  31nMAssay Description:Agonist activity at GST-tagged human FXR-LBD in presence of luorescein-SRC2-2 coactivator peptide by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624067(CHEMBL5428287)
Affinity DataEC50:  37nMAssay Description:Agonist activity at GST-tagged human FXR-LBD in presence of luorescein-SRC2-2 coactivator peptide by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624071(CHEMBL5409962)
Affinity DataEC50:  39nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624068(CHEMBL5422021)
Affinity DataEC50:  41nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624064(CHEMBL5433843)
Affinity DataEC50:  59nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624066(CHEMBL5433336)
Affinity DataEC50:  62nMAssay Description:Agonist activity at GST-tagged human FXR-LBD in presence of luorescein-SRC2-2 coactivator peptide by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624055(CHEMBL5400218)
Affinity DataEC50:  67nMAssay Description:Agonist activity at GST-tagged human FXR-LBD in presence of luorescein-SRC2-2 coactivator peptide by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM21724(3-[(E)-2-(2-chloro-4-{[3-(2,6-dichlorophenyl)-5-(p...)
Affinity DataEC50:  73nMAssay Description:Agonist activity at GST-tagged human FXR-LBD in presence of luorescein-SRC2-2 coactivator peptide by TR-FRET assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624065(CHEMBL5433507)
Affinity DataEC50:  85nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624070(CHEMBL5406974)
Affinity DataEC50:  124nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624067(CHEMBL5428287)
Affinity DataEC50:  127nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM21724(3-[(E)-2-(2-chloro-4-{[3-(2,6-dichlorophenyl)-5-(p...)
Affinity DataEC50:  143nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624057(CHEMBL5433391)
Affinity DataEC50:  147nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624077(CHEMBL5431387)
Affinity DataEC50:  174nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624062(CHEMBL5432874)
Affinity DataEC50:  194nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624063(CHEMBL5412609)
Affinity DataEC50:  197nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624061(CHEMBL5424257)
Affinity DataEC50:  200nMAssay Description:Agonist activity at GST-tagged human FXR-LBD in presence of luorescein-SRC2-2 coactivator peptide by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624056(CHEMBL5425506)
Affinity DataEC50:  236nMAssay Description:Agonist activity at GST-tagged human FXR-LBD in presence of luorescein-SRC2-2 coactivator peptide by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624058(CHEMBL5412701)
Affinity DataEC50:  239nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624074(CHEMBL5427614)
Affinity DataEC50:  256nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624059(CHEMBL5401893)
Affinity DataEC50:  266nMAssay Description:Agonist activity at GST-tagged human FXR-LBD in presence of luorescein-SRC2-2 coactivator peptide by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624066(CHEMBL5433336)
Affinity DataEC50:  336nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624072(CHEMBL5404566)
Affinity DataEC50:  1.19E+3nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624078(CHEMBL5412072)
Affinity DataEC50:  1.24E+3nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624056(CHEMBL5425506)
Affinity DataEC50:  2.09E+3nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624073(CHEMBL5431362)
Affinity DataEC50:  2.34E+3nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624060(CHEMBL5435852)
Affinity DataEC50: >5.00E+3nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624061(CHEMBL5424257)
Affinity DataEC50: >5.00E+3nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624055(CHEMBL5400218)
Affinity DataEC50: >5.00E+3nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624060(CHEMBL5435852)
Affinity DataEC50: >5.00E+3nMAssay Description:Agonist activity at GST-tagged human FXR-LBD in presence of luorescein-SRC2-2 coactivator peptide by TR-FRET assayMore data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624075(CHEMBL5416184)
Affinity DataEC50: >5.00E+3nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624079(CHEMBL5394042)
Affinity DataEC50: >5.00E+3nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetBile acid receptor(Human)
Hepagene Therapeutics

Curated by ChEMBL
LigandPNGBDBM50624059(CHEMBL5401893)
Affinity DataEC50: >5.00E+3nMAssay Description:Agonist activity at human GAL4-FXR-LBD expressed in HEK293T cells assessed as transcriptional activity measured after 16 to 20 hrs by luciferase repo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed